Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...

Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), ...

The treatment for end-stage heart failure continues to rapidly evolve. In the area of mechanical circulatory support, next-generation artificial hearts are ...

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

Jupiter Endovascular announces positive results from SPIRARE I first-in-human study presented at TCT 2025: Menlo Park, California Tuesday, October 28, 2025, 16:00 Hrs [IST] Jupite ...

Anteris Technologies ( ($AU:AVR) ) has issued an announcement. Anteris Technologies announced favorable one-year clinical outcomes for its DurAVR® ...

Researchers have found in a new study that acute kidney injury is a common and serious complication in patients admitted to ...

Antidepressants induce cardiometabolic and other physiological alterations, which vary between medications, according to a ...

The complications highlight pregnancy as a crucial life opportunity for CV health optimization, said investigators led by ...

The low profile Avalus Ultra valve is designed to accommodate diverse patient anatomies. It offers a flexible sewing cuff for ...

Cardiac performance in patients with HF can be determined with measurement of the time for peak oxygen uptake to decrease by more than 12.5%.

GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.